World's Best Scientists 2026 revealed!
Award Badge
Medicine
Korea
2026

D-Index & Metrics

Medicine

D-Index
108
Citations
57583
World Ranking
5903
National Ranking
9

Jeeyun Lee publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jeeyun Lee sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,060 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jeeyun Lee D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jeeyun Lee sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Korea Leader Award

Overview

Jeeyun Lee is affiliated with Sungkyunkwan University in South Korea, specializing in medical research with a primary focus on oncology. Their scholarly output includes nearly 500 publications within the field of medicine, with significant contributions to oncology, pulmonary and respiratory medicine, molecular biology, surgery, and cancer research.

The scientist's research concentrates on several core topics:

  • Gastric Cancer Management and Outcomes
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Gastrointestinal Tumor Research and Treatment
  • Lung Cancer Treatments and Mutations
  • HER2/EGFR in Cancer Research

Frequent publication venues where Jeeyun Lee's work appears include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Pathology - Research and Practice
  • Regular and Young Investigator Award Abstracts
  • Cancer Research and Treatment

Collaborative research is a significant aspect of their work, with the most frequent co-authors being:

  • Seung Tae Kim
  • Won Ki Kang
  • Jung Yong Hong
  • Kyoung-Mee Kim
  • Se Hoon Park

Some notable recent papers involving Jeeyun Lee include:

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer, 2020, New England Journal of Medicine
  • Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer, 2020, JAMA Oncology
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial, 2023, The Lancet Oncology
  • Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials, 2021, JAMA Oncology
  • Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions, 2020, Genome Medicine

The research topics covered by these publications reflect an emphasis on advanced gastric cancer therapies, including immunotherapy and molecular targeted treatments, as well as investigations into tumor microenvironment dynamics.

Best Publications

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

    Razvan Cristescu;Jeeyun Lee;Michael Nebozhyn;Kyoung-Mee Kim

  • Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

    Yung Jue Bang;Young Woo Kim;Han Kwang Yang;Hyun Cheol Chung

  • Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

    Seung Tae Kim;Razvan Cristescu;Adam J. Bass;Kyoung Mee Kim

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

    Kohei Shitara;Yung-Jue Bang;Satoru Iwasa;Naotoshi Sugimoto

  • Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

    Kohei Shitara;Eric Van Cutsem;Yung Jue Bang;Charles Fuchs

  • Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

    Jung Hun Kang;Soon Il Lee;Do Hyoung Lim;Keon Woo Park

  • Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

    Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel

  • Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study

    Jeeyun Lee;Cheolwon Suh;Yeon Hee Park;Young H. Ko

  • Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA

    Richard B. Lanman;Stefanie A. Mortimer;Oliver A. Zill;Dragan Sebisanovic

  • Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

    Jeeyun Lee;Do Hoon Lim;Sung Kim;Se Hoon Park

  • Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Manish R. Patel;John Ellerton;Jeffrey R. Infante;Manish Agrawal

  • HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

    Eric Van Cutsem;Yung-Jue Bang;Feng Feng-yi;Jian M. Xu

  • Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

    Jeeyun Lee;Se Hoon Park;Heung Moon Chang;Jun Suk Kim

  • Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

    Yung Jue Bang;E. Yañez Ruiz;E. Van Cutsem;K. W. Lee

  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses

    Se Hoon Park;Tae Sung Sohn;Jeeyun Lee;Do Hoon Lim

  • Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    Alexander Drilon;Sai Hong Ignatius Ou;Byoung Chul Cho;Dong Wan Kim

  • Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas project

    Bo Hwa Sohn;Jun Eul Hwang;Hee Jin Jang;Hee Jin Jang;Hyun Sung Lee

  • An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.

    Sung Kim;Do Hoon Lim;Jeeyun Lee;Won Ki Kang

Frequent Co-Authors

Won Ki Kang
Won Ki Kang Samsung Medical Center
Joon Oh Park
Joon Oh Park Samsung Medical Center
Ho Yeong Lim
Ho Yeong Lim Samsung Medical Center
Keunchil Park
Keunchil Park The University of Texas MD Anderson Cancer Center
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Ki-Hyun Kim
Ki-Hyun Kim Hanyang University
Jin Seok Ahn
Jin Seok Ahn Sungkyunkwan University
Woong-Yang Park
Woong-Yang Park Samsung Medical Center
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Sun Young Rha
Sun Young Rha Yonsei University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to medicine can open diverse career pathways in healthcare without the need to attend medical school. Programs such as the cheapest online healthcare administration degree are ideal for those interested in leadership roles within hospitals, clinics, and other healthcare settings. These degrees are cost-effective and designed for flexible, remote learning, making them accessible for working professionals.

Advancing your education with a graduate degree like a Master of Healthcare Administration is a strategic step for career growth. It’s important to understand the cost of mha degree options to find affordable programs that still offer strong academic quality.

For registered nurses aiming for the highest levels of practice, there are cheap online dnp programs available that offer flexibility and affordability. Pharmacists can also pursue the 3-year online pharmd to accelerate their education and access new career opportunities.

Carefully comparing program costs, accreditation, and career outcomes helps you choose the best fit for your goals. These online degrees provide scalable options for anyone looking to enter or advance in the healthcare sector.

Best Scientists Citing Jeeyun Lee

Trending Scientists